{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:14:32Z","timestamp":1780078472252,"version":"3.54.0"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T00:00:00Z","timestamp":1364256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vemurafenib is a new\u2010targeted therapy approved for the treatment of patients with <jats:styled-content style=\"fixed-case\">V<\/jats:styled-content>600<jats:styled-content style=\"fixed-case\">E BRAF<\/jats:styled-content>\u2010mutant metastatic melanoma. Among the cutaneous adverse events reported, the photosensitivity is frequently experienced. We aimed to characterize more deeply the mechanism leading to this photosensitivity as well as the corresponding <jats:styled-content style=\"fixed-case\">UV<\/jats:styled-content> spectrum. Phototests showed that the phototoxicity was <jats:styled-content style=\"fixed-case\">UVA<\/jats:styled-content>\u2010dependent since from normal value prior to vemurafenib treatment, the <jats:styled-content style=\"fixed-case\">UVA<\/jats:styled-content>\u2010minimal erythema dose decreased in 17 of 18 patients (94.4%) while the minimal erythema dose remained unchanged. Furthermore, a vemurafenib\u2010induced erythema appeared quickly during the <jats:styled-content style=\"fixed-case\">UVA<\/jats:styled-content> exposure contrarily to what is observed with a conventional drug\u2010induced phototoxicity showing an erythema 12\u201324\u00a0h after the phototesting. Vitamin <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content> concentration decreased, and porphyrin level significantly increased after 2\u00a0months of vemurafenib. Our study confirms the high risk of vemurafenib\u2010induced photosensitivity and indicates that it is possibly vitamin <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>\u2010 and porphyrin dependent.<\/jats:p>","DOI":"10.1111\/exd.12119","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T17:37:29Z","timestamp":1360949849000},"page":"297-298","source":"Crossref","is-referenced-by-count":76,"title":["Vemurafenib: an unusual <scp>UVA<\/scp>\u2010induced photosensitivity"],"prefix":"10.1111","volume":"22","author":[{"given":"Pauline","family":"Gelot","sequence":"first","affiliation":[{"name":"Oncodermatology Unit CHU Hotel Dieu Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dutartre","sequence":"additional","affiliation":[{"name":"Oncodermatology Unit CHU Hotel Dieu Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Khammari","sequence":"additional","affiliation":[{"name":"Oncodermatology Unit CHU Hotel Dieu Nantes France"},{"name":"Inserm U892\u2010CNRS U6299 CIC Bioth\u00e9rapie Inserm 0503 Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Boisrobert","sequence":"additional","affiliation":[{"name":"Oncodermatology Unit CHU Hotel Dieu Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Centre Fran\u00e7ais des Porphyries Service de Biochimie H\u00f4pital Louis Mourier APHP Colombes France"},{"name":"Inserm U773 Centre de Recherche Biom\u00e9dicale Bichat Beaujon CRB3 Universit\u00e9 Paris Diderot, site Bichat Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Charles","family":"Deybach","sequence":"additional","affiliation":[{"name":"Centre Fran\u00e7ais des Porphyries Service de Biochimie H\u00f4pital Louis Mourier APHP Colombes France"},{"name":"Inserm U773 Centre de Recherche Biom\u00e9dicale Bichat Beaujon CRB3 Universit\u00e9 Paris Diderot, site Bichat Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Michel","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics Unit CHU Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Seit\u00e9","sequence":"additional","affiliation":[{"name":"La Roche\u2010Posay Pharmaceutical Laboratories Asni\u00e8res France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[{"name":"Oncodermatology Unit CHU Hotel Dieu Nantes France"},{"name":"Inserm U892\u2010CNRS U6299 CIC Bioth\u00e9rapie Inserm 0503 Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,26]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09454"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1113752"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.43"},{"key":"e_1_2_4_8_1","first-page":"123","volume":"114","author":"B\u00e9ani J C","year":"1987","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2009.00391.x"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.allerg.2008.04.003"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.020"},{"key":"e_1_2_4_12_1","first-page":"2","volume":"26","author":"Magnus I A","year":"1961","journal-title":"Lancet"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.08.003"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10163.x"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01551.x"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1039\/C1PP05152K"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04139.x"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fexd.12119","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.12119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T22:42:42Z","timestamp":1698705762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.12119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,26]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/exd.12119"],"URL":"https:\/\/doi.org\/10.1111\/exd.12119","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,26]]}}}